QR12000 Compound Tablets in Patients with Moderate to Severe Essential Hypertension

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 810 participants.

Also called NCT06716970

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 810 participants (planned count) (from the registry)
Sponsor
Wuhan Createrna Science and Technology Co., Ltd (from the registry)
Registry
  • NCT NCT06716970
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT06716970. Randomized; quadruple masking; primary purpose treatment. Start 2024-12-30 (anticipated); primary completion 2026-04-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
QR12000 Compound Tablets in Patients with Moderate to Severe Essential Hypertension
Condition
Essential Hypertension
Intervention (Drug)
QR12000 75mg
Intervention (Drug)
QR12000 75mg placebo
Intervention (Drug)
QR12000 150mg
Intervention (Drug)
QR12000 150mg placebo
Intervention (Drug)
Sacubitril/valsartan 200mg
Intervention (Drug)
Sacubitril/valsartan 200mg placebo
Lead sponsor
Wuhan Createrna Science and Technology Co., Ltd (class: industry)

Record details

Record id
cardio:ct-nct06716970
Content hash
8761ca7f780b71779c03dc44eaff222e15604531db80edc2e599f4703c15942c